Glyphase MP 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This formulation integrates three complementary mechanisms of action to improve glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. Pioglitazone, a thiazolidinedione, further enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), promoting glucose uptake in adipose tissue and muscle. The combination is particularly beneficial for patients inadequately controlled on monotherapy or dual therapy, providing synergistic effects on fasting and postprandial blood glucose levels. Glyphase MP 2 Tablet PR should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal or hepatic impairment, congestive heart failure, or a history of bladder cancer due to Pioglitazone’s risk profile. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended. This combination therapy offers an effective and convenient option for optimizing glycemic control in type 2 diabetes management.